Key Takeaways:

• Developers, faced with oversupply and weakening demand, are offloading their life sciences inventory, with some even marketing planned life sciences spaces as office space.
• Although fewer deals have been completed in 2024, venture capital funding has risen by 20% compared to the same period last year, signaling that the deals made are more significant.
• M&A activity surged by 92.6% from Q3 2023 to Q3 2024 across the life sciences sector, with acquisitions occurring among both large pharmaceutical companies and startups.